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Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of
lupus nephritis: a metaanalysis of randomized controlled trials
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Background/aim: Multitarget therapy for lupus nephritis (LN) remains in its exploratory phrase and the recent evidence is insufficient.
This study aimed to evaluate the efficacy and safety of mycophenolate mofetil (MMF), tacrolimus (TAC), and steroids (multitarget
therapy) versus intravenous cyclophosphamide (IVC) and steroids in induction treatment of LN.
Materials and methods: We searched for randomized controlled trials of MMF plus TAC versus IVC in LN using PubMed, EMBASE, the
Cochrane Central Register of Controlled Trials, the China Biology Medicine Database, and the China National Knowledge Infrastructure
Database. We assessed the retrieved citations and selected studies according to predefined inclusion and exclusion criteria.
Results: In total, we identified 8 trials including 801 patients. The metaanalysis revealed that overall multitarget therapy is more effective
at inducing complete renal remission compared with IVC (RR: 1.94, 95% CI: 1.61–2.33; P < 0.00001). In terms of LN classification,
multitarget therapy exhibited superiority compared with IVC for inducing complete remission of class IV LN (RR: 1.52, 95% CI: 1.10–
2.08; P = 0.01), class V LN (RR: 4.24, 95% CI: 1.30–13.88; P = 0.02), and class V+IV LN (RR: 2.29, 95% CI: 1.45–3.62; P = 0.0004);
however, no superiority was noted for class III LN or class V+III LN. The rates of gastrointestinal symptoms, abnormal liver function,
leukopenia, and irregular menstruation were significantly reduced in the multitarget therapy group compared with the IVC group for
LN. Nevertheless, the multitarget therapy group more frequently exhibited new-onset hypertension compared with the IVC group.
Conclusion: Multitarget therapy is more effective than IVC in the induction treatment of LN in Chinese patients and exhibits a better
safety profile.
Key words: Lupus nephritis, cyclophosphamide, mycophenolate mofetil, tacrolimus, metaanalysis.

1. Introduction
Lupus nephritis (LN) remains a common complication of
systemic lupus erythematosus (SLE); it has a considerable
influence on patient outcomes and is associated with a
sixfold increase in mortality compared with the general
population (1,2). The main goals of treating LN are to
induce renal remission and to prevent renal flares and
end-stage renal disease. Patients with complete remission
exhibit better clinical outcomes compared with patients
with partial remission and especially patients who do not
respond to treatment (3,4). The use of immunosuppressive
drugs has improved the remission rates and long-term
renal survival in recent decades. The combination of
corticosteroids and cyclophosphamide (CYC) and/or
mycophenolate mofetil (MMF) is recommended as the
current induction therapy for LN; however, the complete

remission rate remains inadequate (5–10). Previous studies
demonstrated that the remission rate of patients with class
V+IV LN was only 21%–27% with the CYC treatment
regimen (11,12). Under treatment with MMF or tacrolimus
(TAC), patients with class V+IV LN obtained a complete
remission rate of only 20% to 21.1% (13, 14). Moreover,
adverse effects such as amenorrhea, hemorrhagic cystitis,
sepsis, and malignancy events exhibited high rates (15). To
identify a more effective and safer therapy, Liu et al. (16)
proposed and studied multitarget therapy, the combination
of MMF, TAC, and steroids, for LN induction treatment.
Multitarget therapy exhibited a significantly increased
complete remission rate at 24 weeks (45.9%) compared
with intravenous cyclophosphamide (IVC) (25.6%).
Furthermore, adverse events were observed less frequently
in the multitarget therapy group. Multitarget therapy has
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also been utilized in the treatment of both proliferative
and membranous LN (17,18). Currently, increasing
research emphasizes the role of multitarget treatment
for LN (19–21). However, these studies included a small
sample size and the pathological classes of patients varied.
Therefore, we performed this metaanalysis of randomized
controlled trials (RCTs) to evaluate the efficacy and safety
of multitarget therapy versus IVC as induction therapy in
different LN pathological classes.
2. Materials and methods
2.1. Inclusion criteria
Two authors assessed studies for inclusion in this
metaanalysis based on the following criteria: 1) the
study involved patients who had been diagnosed with
SLE according to the criteria of the American College of
Rheumatology and biopsy-proven LN class III, IV, V, V+III,
or V+IV according to the ISN/RPS 2003 classification; 2)
the study compared the efficacy and safety of TAC plus
MMF with IVC; and 3) it was a RCT. Retrospective studies
and non-RCTs were excluded.
2.2. Search strategy
We searched PubMed, EMBASE, the Cochrane Central
Register of Controlled Trials, the China Biology Medicine
Database (CBM), and the China National Knowledge
Infrastructure Database (CNKI) (all to May 2017) without
any restrictions. The search terms ‘lupus nephritis’,
‘tacrolimus’ and ‘mycophenolate mofetil’ and their related
terms were employed. We assessed the reference lists of
all included studies to identify other potentially relevant
trials.
2.3. Study selection
Two authors separately examined the titles and abstracts of
all retrieved studies and excluded studies that clearly did
not meet the inclusion criteria. The full texts of studies that
appeared to meet the inclusion criteria or were uncertain
were searched. Then two authors assessed these studies
independently to establish whether they could be included.
In cases of disagreement, a third author was asked to give
an opinion to resolve the issue.
2.4. Data extraction and management
Two authors independently extracted information on
the study design, baseline characteristics of patients,
intervention and control treatment, outcome data, and
definitions of outcomes from studies. In cases of missing
data, we contacted the original authors to obtain the
required information. Any differences in data extraction
were resolved by discussion.
2.5. Study quality assessment
The quality of included studies was evaluated using the
Cochrane Handbook (22). The risk of bias comprised a

902

description and judgment based on the following criteria:
random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, selective
reporting, and other source of bias. Each criterion was
judged as ‘Low risk of bias’, ‘Unclear risk of bias’, or ‘High
risk of bias’. Two authors separately evaluated the quality of
the included studies. In cases of disagreement, consensus
was reached by discussion.
2.6. Statistical analysis
Statistical analyses were performed with Cochrane
RevMan 5.3 (23). The risk ratio (RR) and 95% confidence
interval (CI) were calculated for dichotomous data. The
mean difference (MD) and 95% CI were used to report
continuous data. Clinical heterogeneity was assessed
by considering the design of each study. If no clinical
heterogeneity was observed, statistical heterogeneity
was evaluated using the chi-square test (P < 0.1 indicates
significance) and quantified using the I2 statistic (I2 value
> 50% indicates significant heterogeneity) (22). If
heterogeneity did not exist among studies, a fixed-effect
model was utilized. If significant statistical heterogeneity
was noted, a random-effects model was utilized instead
of the fixed-effect model, which was employed for studies
that appeared to be clinically and methodologically
homogeneous. Subgroup analysis was planned to explore
the treatment effects for different LN pathological classes.
3. Results
3.1. Study selection
Our electronic search identified 579 studies, including
489 in English and 90 in Chinese. In total, 535 studies,
including duplicate references, reviews, basic research,
meeting abstracts, case reports, and non-RCTs, were
excluded after title and abstract examination. The full
texts of the remaining 24 articles were retrieved for further
review. Finally, eight eligible citations (16–21,24,25),
including two in English and six in Chinese, were included
in the metaanalysis (Figure 1).
3.2. Study characteristics and quality assessment
The baseline characteristics of the included studies are
summarized in Table 1 and the risks of bias are presented
in Figure 2. These eight studies involved a total of 801
patients, including 671 female patients. In total, 406
patients were treated with multitarget therapy and 395
were treated with IVC. All of the included studies provided
a statement regarding randomization; however, only four
studies explained random sequence generation that was
computer-generated (16,17,19,25). Four trials reported
withdrawals and dropouts (16–19). The main study
limitation was a failure to explain blinding or the lack of a
double-blind design.
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Figure 1. Study selection flowchart.

Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages
across all included studies.

3.3. The efficacy of multitarget therapy versus IVC for LN
The complete remission rate was reported in all eight
trials. No significant heterogeneity was noted among
studies; thus, the fixed-effect model was used. Based on
the metaanalysis results, the complete remission rate
of the multitarget group was significantly increased

compared with the IVC group (RR: 1.94, 95% CI: 1.61–
2.33; P < 0.00001) (Figure 3). Subgroup analysis revealed
that multitarget therapy was superior to IVC for inducing
a complete remission of class IV LN (RR: 1.52, 95% CI:
1.10–2.08; P = 0.01) and class V LN (RR: 4.24, 95% CI:
1.30–13.88; P = 0.02) and significantly superior for class
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904
M: 25.1 ± 9.4
C: 30.5 ± 8.9

M: 25.2 ± 8.9
C: 30.6 ± 4.6

M: 4.41 ± 1.95
C: 4.10 ± 1.20

M: 0.87 ± 0.21
C: 0.89 ± 0.30

M: 23.9 ± 5.7
C: 24.6 ± 3.9

M: 12 (60)
C: 12 (60)

M: 20 (100)
C: 19 (95)

Age (years)

Urine protein
(g/24 h)

Serum creatinine
(mg/dL)

Serum albumin
(g/L)

Anti-dsDNA
Positive [n (%)]

Serum C3 <0.79g/L
[n (%)]

M: 14.9 ± 4.0
C: 14.0 ± 2.4

9 months

SLE-DAI

Duration

Pathologic class
M: 0/0/0/0/20
[n (III/IV/V/V+III/V+IV)] C: 0/0/0/0/20

M: 6/39
C: 4/30

M: 4/16
C: 2/18

Sex (M/F)

9 months

Unclear

M: 0/18/0/11/16
C: 0/13/0/9/12

M: 0.59 ± 0.26†
C: 0.53 ± 0.23†

M: 17 (37.7)
C: 13 (38.2)

M: 30.7 ± 6.5
C: 28.8 ± 6.5

M: 0.82 ± 0.26
C: 0.86 ± 0.35

M: 3.5 ± 2.0
C: 3.6 ± 2.0

Hu et al.,
2011 (18)

Bao et al.,
2008 (17)

Characteristic

Table 1. Baseline characteristics of included studies.

M: 23/168
C: 20/161

Liu et al.,
2015 (16)

9 months

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

24 weeks

M: 16.0 (12.0–18.0) ‡
C: 15.0 (12.0–18.0) ‡

M: 10/74/32/19/46
C: 9/76/37/7/52

M: 0.44 (0.34–0.62) ‡
C: 0.43 (0.34–0.63) ‡

M: 106 (59.2)
C: 113 (63.1)

24 weeks

Unclear

Unclear

Unclear

Unclear

Unclear

Unclear

M: 0.77 (0.63–1.04) ‡
C: 0.82 (0.64–1.05) ‡
M: 26.0 (21.5–30.7) ‡
C: 25.1 (20.1–31.0) ‡

Unclear

M: 30.4 ± 12.8
C: 30.6 ± 12.7

M: 11/19
C: 10/20

Zhang et al.,
2016 (25)

M: 3.44 (2.24–5.49) ‡
C: 3.68 (2.41–5.38) ‡

M: 35.2 ± 5.4 M: 30.3 (23.3–38.6) ‡
C: 35.2 ± 5.4 C: 33.6 (24.2–41.5) ‡

M: 19/9
C: 18/10

Li,
2014 (24)

M: 5/31
C: 6/30

Jiang et al.,
2017 (21)

9 months

M: 16.0 ± 5.9
C: 17.0 ± 4.1

T: 5/41/16/6/17§

M: 0.65 ± 0.13†
C: 0.66 ± 0.06†

M: 34 (68.0)
C: 33 (66.0)

M: 23.3 ± 3.86
C: 22.1 ± 4.37

36 weeks

M: 16.2 ± 5.4
C: 15.7 ± 5.8

M: 1/8/2/1/4
C: 2/7/2/2/3

Unclear

M: 14 (87.5)
C: 13 (81.3)

M: 26.8 ± 6.4
C: 27.2 ± 5.8

6 months

M: 15.50 ± 3.25
C: 16.22 ± 4.11

M: 15/13/8/0/0
C: 13/14/9/0/0

M: 0.61 ± 0.18†
C: 0.58 ± 0.11†

M: 23 (63.89)
C: 24 (66.67)

M: 25.76 ± 6.97
C: 26.11 ± 7.22

M: 1.07 ± 0.20
C: 1.06 ± 0.19

M: 1.49 ± 1.03
C: 1.52 ± 0.76

Unclear

M: 3.92 ± 0.64 M: 4.94 ± 2.12
C: 3.97 ± 0.55 C: 5.01 ± 2.55

M: 35.8 ± 13.9 M: 29.1 ± 5.5
C: 35.6 ± 13.6 C: 28.7 ± 5.3

M: 3/13
C: 2/14

Huang et al.,
2017 (20)

M: 5.10 ± 3.16
C: 4.92 ± 2.20

M: 31.2 ± 10.3
C: 33.2 ± 11.6

M: 3/47
C: 4/46

Zhao and Xu,
2016 (19)
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Proteinuria <0.4
g/24 h with normal
urinary sediment,
serum albumin ≥35
g/L, normal serum
creatinine range

Proteinuria
<0.3 g/24 h
with normal
urinary
sediment,
normal serum
albumin,
normal serum
creatinine
range

Proteinuria
<0.4 g/24 h with
normal urinary
sediment, serum
albumin ≥35 g/L,
normal serum
creatinine range

Jiang et al., 2017
(21)

Values expressed as M ± SD. To convert creatinine value to mg/dL, multiply by 0.0113. M, Multitarget therapy group; C, cyclophosphamide group; T, total; SLE-DAI, Systemic Lupus
Erythematosus Disease Activity Index. †Values expressed as M ± SD. ‡Values expressed as number (percentage), median (25th–75th percentiles). §Values include pathologic class
II, 15 cases.
M, Multitarget therapy group; C, cyclophosphamide group; AUC, area under the time concentration curve; MP, methylprednisolone; AZA, azathioprine; MPA, mycophenolate acid.

Definition
of complete
remission

Proteinuria <0.4
g/24 h with normal
urinary sediment,
serum albumin ≥35
g/L, normal serum
creatinine range or
not >15% more than
baseline values

Huang et al.,
2017 (20)

Proteinuria
<0.3 g/24 h with
normal urinary
sediment,
serum albumin
≥35 g/L,
normal serum
creatinine range
or not >15%
more than
baseline values

Zhao and Xu,
2016 (19)

M: TAC (3–4
mg/day),
maintain a blood
concentration
within 10 ng/mL,
MMF (0.75–1 g/
day), maintain
AUC from 0 to 12
h of MPA within
45 mg h/L
C: IVC 0.5–1 g/
m2 monthly for 6
months
All patients
received MP
pulse therapy
followed by oral
prednisone

Zhang et al.,
2016 (25)

M: TAC (3–4
mg/day),
maintain
M: TAC 0.15
M: TAC 4 mg/ M: TAC (2–4
a blood
mg/kg daily,
day, MMF 1g/
mg/day), MMF
MMF 50 mg/kg concentration
day
(0.5–1 g/day)
within 5–7
daily
C: IVC 0.5–1 g/ C: IVC 8–12 mg/
ng/mL, MMF
C:
IVC
0.8–1
g
m2 monthly for kg monthly for
monthly for 9 (0.75–1 g/day)
24 weeks
24 weeks
C: IVC 0.5–1 g/
months
All patients
All patients
m2 monthly for
All patients
received MP
received MP
received MP
24–36 weeks
pulse therapy
pulse therapy
pulse therapy
All patients
followed by oral followed by oral
followed by
received MP
prednisone
prednisone
oral prednisone pulse therapy
followed by oral
prednisone

Liu et al., 2015
(16)

Proteinuria
<0.4 g/24 h with
Proteinuria
Proteinuria
<0.4 g/24 h with <0.4 g/24 h with normal urinary
normal urinary normal urinary sediment, serum
albumin ≥35
sediment,
sediment,
serum albumin serum albumin g/L, normal
serum creatinine
≥35 g/L,
≥35 g/L,
normal serum range or not
normal serum
creatinine range creatinine range >15% more than
baseline values

Treatment
regimen

Li, 2014 (24)

M: TAC 4 mg/
M: TAC 4 mg/day,
day,
M: TAC 3–4 mg/
maintain a blood
MMF 1 g/day
day, maintain a blood
concentration within C: IVC was
concentration within
initiated at a
5–7 ng/mL, MMF 0.75– 4–7 ng/mL, MMF 1
1 g/day, maintain AUC g/day, maintain AUC dose of 0.75
from 0 to 12 h of MPA from 0 to 12 h of MPA g/m2 and
at 20–30 mg h/L
at 20–45 mg h/L
maximum dose
C: IVC 0.5–1 g/
C: IVC 0.5–1g/m2
less than 1.2 g
m2 monthly for 6–9
monthly for 6–9
monthly for 6–9
months
months.
months
All patients
All patients received
All patients received
received MP
MP pulse therapy
MP pulse therapy
pulse therapy
followed by oral
followed by oral
followed by oral
prednisone
prednisone
prednisone

Hu et al., 2011 (18)

Bao et al., 2008 (17)

Characteristic

Table 1. (Continued).
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Figure 3. Forest plot of the effects of multitarget therapy versus IVC on complete remission rate in different pathological LN classes.
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V+IV LN (RR: 2.29, 95% CI: 1.45–3.62; P = 0.0004);
however, superiority was not observed for class III and
class V+III LN (Figure 3).
Two trials reported the changes in urine protein
and serum albumin after treatment. Multitarget therapy
significantly reduced urine protein (MD: -1.07, 95%
CI: -2.01 to -0.13; P = 0.03) (Figure 4) and increased
serum albumin (MD: 1.96, 95% CI: 0.63–3.29; P = 0.004)
(Figure 5) compared with IVC. No obvious heterogeneity
was noted between these studies.
The anti-dsDNA negative conversion rates and serum
C3 normalization rates were reported by four studies and

one study, respectively. Based on the metaanalysis results,
the anti-dsDNA negative conversion rate of the multitarget
group was significantly increased compared with that of
the IVC group (RR: 1.55, 95% CI: 1.06–2.26; P = 0.02) and
only one group reported serum C3 normalization rates
(RR: 1.31, 95% CI: 0.68–2.53; P = 0.43) (Figure 6). No
obvious heterogeneity was noted between these studies.
3.4. The safety of multitarget therapy versus IVC for LN
The results of adverse events comparing multitarget
therapy with IVC are presented in Table 2. No significant
heterogeneity was noted among studies as evaluated by the
I2 statistic of 0% or 53% and thus the fixed-effect model

Figure 4. Forest plot of the effects of multitarget therapy versus IVC on urine protein in LN.

Figure 5. Forest plot of the effects of multitarget therapy versus IVC on serum albumin in LN.

Figure 6. Forest plot of the effects of multitarget therapy versus IVC on anti-dsDNA negative conversion rate and serum C3 normalization
rate in LN.
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was used. The metaanalysis results indicated that the rates
of gastrointestinal symptoms, abnormal liver function,
leukopenia, and irregular menstruation were significantly
reduced in the multitarget therapy group compared
with the IVC group. The rates of infection, alopecia, and
hyperglycemia were similar between the two groups.
However, the multitarget therapy group more frequently
exhibited new-onset hypertension compared with the IVC
group.
4. Discussion
LN renal lesions vary from minimal lesions to advanced
sclerosis, which may lead to end-stage renal disease.
The optimal choice for treating LN should consider the
pathological class and severity (26). The combination of
corticosteroids and CYC and/or MMF is recommended
as the current induction therapy for LN (5–7). A previous
study demonstrated that the role of MMF is not clear in
treating LN and it should not be recommended as the
induction drug for severe LN (27). Thus, treating the severe
pathological class of LN remains challenging. Immune
dysregulation is fundamental to the pathogenesis of LN,
as both B and T cells are involved in the development of
the disease. MMF, a lymphocyte-selective antiproliferative
agent, has proven to be an effective and safe therapy
in LN in a number of RCTs (28–30) and metaanalyses
(31,32). TAC, a T cell-specific calcineurin inhibitor, has
emerged as an effective and safe immunosuppressive drug
for treating LN (33–35). MMF plus TAC has been used
in organ transplantation patients for years (36) and is a
useful therapy for early mixed cellular and humoral renal
allograft rejections (37). Liu et al. (16) demonstrated that
multitarget therapy for LN is more effective than a single
agent. The publication of their results inspired a new wave
of relevant research (19–21,25). To better understand the

efficacy and safety of multitarget therapy versus IVC as
induction therapy in different LN pathological classes,
the present metaanalysis with subgroup analysis was
performed.
The main finding based on this metaanalysis is
that multitarget therapy exhibits significant superiority
compared with IVC for inducing complete remission
of LN, particularly V+IV. However, no superiority
was noted for class III and class V+III LN. The rates of
gastrointestinal symptoms, abnormal liver function,
leukopenia, and irregular menstruation were significantly
reduced in the multitarget therapy group compared with
those of the IVC group for LN. The rates of infection,
alopecia, and hyperglycemia were similar between groups.
However, the multitarget therapy group exhibited newonset hypertension more frequently than the IVC group.
Moreover, multitarget therapy significantly reduced urine
protein, increased serum albumin, and significantly
increased the anti-dsDNA negative conversion rate
compared with the IVC group.
There are several limitations to this metaanalysis.
First, only one or two studies were included in some
subgroup analyses. Thus, the findings should be regarded
with caution and more large-scale RCTs are needed to
confirm these results. Second, the included studies mostly
were small-scale and no trial was double-blinded. Third,
the participants in the included studies were exclusively
Chinese. The efficacy and safety of multitarget therapy
for LN in other races should be proven in further studies.
Finally, the included studies reported the short-term
outcomes of induction treatment; thus, the long-term
efficacy and toxicity of multitarget therapy for LN patients
must be proven by further long-term studies.
Our metaanalysis of current RCTs suggested that
multitarget therapy is more effective than IVC for

Table 2 Metaanalysis of adverse events.
Outcomes

Studies Multitarget therapy IVC

Heterogeneity (P, I2)

RR

95% CI

P-value

Gastrointestinal symptoms

7

42/376

82/365

0.05, 53%

0.51

0.37–0.71

<0.0001

Abnormal liver function

6

11/362

25/351

0.68, 0%

0.44

0.23–0.86

0.02

Leukopenia

7

11/376

34/365

0.31,16%

0.33

0.18–0.63

0.0006

Infection

7

125/378

133/367

0.35, 10%

0.93

0.78–1.11

0.42

Irregular menstruation

5

6/279

18/265

0.84, 0%

0.36

0.16–0.84

0.02

Alopecia

5

11/332

21/321

0.78, 0%

0.52

0.26–1.05

0.07

Hyperglycemia

3

7/246

6/235

0.54,0%

1.09

0.39–3.02

0.87

New-onset hypertension

5

23/304

6/293

0.88, 0%

3.14

1.40–7.04

0.006

IVC, Intravenous cyclophosphamide; RR, relative risk; CI, confidence interval. RR < 1 favors multitarget therapy; RR > 1 favors IVC
group.
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inducing a complete remission of LN, especially for class
V+IV Chinese patients, and exhibits a better safety profile.
Further large-scale high-quality RCTs are needed to
confirm these results.
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